Disease · MONDO_0005058
leiomyosarcoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. leiomyosarcoma. Diseases, record MONDO_0005058. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005058
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Leiomyosarcomas, leiomyosarcoma (excluding uterine leiomyosarcoma), leiomyosarcoma - not uterine, leiomyosarcoma, malignant
- Open Targets
Drugs82
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TRABECTEDIN | CHEMBL450449 | Small molecule | Approval | DailyMed | 20 | 19 | 19 | Drugs and targets |
| GEMCITABINE | CHEMBL888 | Small molecule | Phase 3 | ClinicalTrials.gov | 17 | 17 | 17 | Drugs and targets |
| DOXORUBICIN | CHEMBL53463 | Small molecule | Phase 3 | ClinicalTrials.gov | 12 | 12 | 12 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| DACARBAZINE | CHEMBL476 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| GEMCITABINE HYDROCHLORIDE | CHEMBL1637 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 4 | Drugs and targets |
| DOXORUBICIN HYDROCHLORIDE | CHEMBL359744 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| ERIBULIN | CHEMBL1683590 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| PAZOPANIB | CHEMBL477772 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
1 to 10 of 82
See all 82 drugsTargets94
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KDR | Vascular endothelial growth factor receptor | 9 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 8 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 7 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 7 | Stem cell growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 7 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| PDGFRA | Platelet-derived growth factor receptor | 6 | Platelet-derived growth factor receptor alpha antagonist; Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/5156 | Drugs and targets |
| TUBA1A | Tubulin | 5 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 5 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 5 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 5 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7278 | Drugs and targets |
1 to 10 of 94
See all 94 targetsTrials106
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01343277 | A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma | Phase 3 | 579 | 2016-01-28 | Advanced Liposarcoma or Leiomyosarcoma | DACARBAZINE, TRABECTEDIN | Its record names the disease | ClinicalTrials.gov |
| NCT01327885 | Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma | Phase 3 | 452 | 2017-02-28 | Soft Tissue Sarcoma | DACARBAZINE, ERIBULIN MESYLATE | Its record names the disease | ClinicalTrials.gov |
| NCT05269355 | A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) | Phase 2/3 | 359 | 2025-06-13 | Leiomyosarcoma | UNESBULIN | Its record names the disease | ClinicalTrials.gov |
| NCT02501096 | A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors | Phase 1/2 | 357 | 2023-07-20 | Tumors | LENVATINIB, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00060944 | A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | Phase 2 | 271 | 2014-09-08 | Liposarcoma, Leiomyosarcoma | TRABECTEDIN | Its record names the disease | ClinicalTrials.gov |
| NCT03565991 | Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors | Phase 2 | 202 | 2023-08-07 | Locally Advanced or Metastatic Solid Tumors, Genes, BRCA 1 | AVELUMAB, TALAZOPARIB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT03013491 | PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | Phase 1/2 | 196 | 2025-06-17 | Solid Tumor, Lymphoma | IPILIMUMAB, PACMILIMAB, VEMURAFENIB | Its record names the disease | ClinicalTrials.gov |
| NCT02406781 | Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial | Phase 2 | 129 | 2025-12-10 | Sarcoma | CYCLOPHOSPHAMIDE, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00668148 | A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma | Phase 2 | 113 | 2018-07-17 | Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET), Rhabdomyosarcoma, Leiomyosarcoma, Adipocytic Sarcoma, Synovial Sarcoma | CIXUTUMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01012297 | Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma | Phase 3 | 107 | 2017-07-14 | Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma | BEVACIZUMAB, DOCETAXEL, GEMCITABINE HYDROCHLORIDE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
1 to 10 of 106
See all 106 trialsComparisons in its trials23
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Trabectedin vs Dacarbazine: serious adverse events | 155 of 378 | 52 of 172 | 550 | NCT01343277 | Trial comparisons |
| Arm A: Eribulin Mesylate vs Arm B: Dacarbazine: deaths from any cause | 198 of 228 | 206 of 224 | 452 | NCT01327885 | Trial comparisons |
| Arm A: Eribulin Mesylate vs Arm B: Dacarbazine: serious adverse events | 76 of 228 | 71 of 224 | 452 | NCT01327885 | Trial comparisons |
| Unesbulin and Dacarbazine vs Placebo and Dacarbazine: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 236 of 238 | 112 of 120 | 358 | NCT05269355 | Trial comparisons |
| Unesbulin and Dacarbazine vs Placebo and Dacarbazine: deaths from any cause | 49 of 238 | 27 of 120 | 358 | NCT05269355 | Trial comparisons |
| Unesbulin and Dacarbazine vs Placebo and Dacarbazine: serious adverse events | 81 of 238 | 43 of 120 | 358 | NCT05269355 | Trial comparisons |
| Trabectedin 1.5 mg/m2 vs Trabectedin 0.58 mg/m2: serious adverse events | 48 of 130 | 41 of 130 | 260 | NCT00060944 | Trial comparisons |
| Cohort 1 (BRCA 1/2 Defect) vs Cohort 2 (ATM Defect): Number of Participants With Positive Programmed Death Ligand 1 (PD-L1) Expression in Baseline Tumor Tissue | 27 of 159 | 0 of 41 | 200 | NCT03565991 | Trial comparisons |
| Cohort 1 (BRCA 1/2 Defect) vs Cohort 2 (ATM Defect): deaths from any cause | 15 of 159 | 3 of 41 | 200 | NCT03565991 | Trial comparisons |
| Cohort 1 (BRCA 1/2 Defect) vs Cohort 2 (ATM Defect): serious adverse events | 50 of 159 | 7 of 41 | 200 | NCT03565991 | Trial comparisons |
1 to 10 of 23
See all 23 comparisons in its trialsPapers from its trials80
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005058
GET https://conductscience.org/api/diseases/v1/MONDO_0005058/drugs?page=2